Galecto, Inc. (GLTO)
Market Cap | 16.41M |
Revenue (ttm) | n/a |
Net Income (ttm) | -45.94M |
Shares Out | 27.11M |
EPS (ttm) | -1.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 26,697 |
Open | 0.600 |
Previous Close | 0.600 |
Day's Range | 0.600 - 0.620 |
52-Week Range | 0.500 - 3.700 |
Beta | 1.01 |
Analysts | Buy |
Price Target | 9.00 (+1,387.6%) |
Earnings Date | Nov 6, 2023 |
About GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small mo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GLTO stock is "Buy." The 12-month stock price forecast is $9.0, which is an increase of 1,387.60% from the latest price.
News

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks Partial response seen in three of five pa...

Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced ...

Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f...

Galecto shares drop 65% as biotech halts development of lung-disease treatment
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease...

Galecto to discontinue development of lung disease treatment
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study.

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases Announces next steps for clinical development plan in severe liver diseases

Galecto Reports Second Quarter Operating and Financial Results
BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f...

Galecto Set to Join Russell Microcap® Index
BOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f...

Galecto to Present at the Upcoming Jefferies Healthcare Conference
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi...

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi...

Galecto to Present Poster at Upcoming ATS 2023 International Conference
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi...

Galecto Reports First Quarter Operating and Financial Results
BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for ...

Galecto to Present Two Posters at AACR Annual Meeting 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for ...

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for ...

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments fo...

Galecto to Participate in SVB Securities Global Biopharma Conference
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for...

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients

Galecto Reports Third Quarter Operating and Financial Results
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for...

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for...

Galecto to Participate in Jefferies London Healthcare Conference
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for...

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for...

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study a combination of pembrolizumab and a galectin-3 inhibitor Phase 2 inves...

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022
BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t...
Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis
Galecto, a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, has announced positive results from intermediate assessment of its ongoing Phase...

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET